Corvex completed the investment in Fortrea.

Corvex, a New York-based hedge fund, completed the investment in Fortrea, a clinical trials management company. Financial terms were not disclosed. The company’s shares, which have fallen 49% this year, closed down 6% to $17.80 each on October 22. The shares rose more than 5% after the close of regular trading.